Panoramic: Automotive and Mobility 2025
John Brockland
Partner Intellectual Property
John focuses on strategic and commercial transactions involving the development, transfer, and licensing of technology and IP assets, as well as the provision of technology-related services.
John has years of experience drafting, negotiating, and counseling on joint-development, licensing, distribution, and reseller agreements in the fields of semiconductors, software, hardware, electronic commerce, and internet services. He is also highly experienced in advising clients on issues related to open-source licensing models and regularly counsels on information technology and business process outsourcing arrangements.
John also oversees and advises on significant IP and commercial due diligence investigations in the context of M&A transactions, and handles IP and technology agreements in carve-outs, spin-offs, and other strategic transactions.
Leading legal guides recognize John's standing in the IP and technology fields. Chambers USA and Chambers Global rank him as a leading lawyer for Technology Transactions; IAM Patent 1000 recommends him for licensing in California; and Managing Intellectual Property IP Stars has named him an "IP Star."
At Hogan Lovells, John serves as the global head of the firm's Technology industry sector and as a member of the IP practice leadership team.
Known for his wide-ranging knowledge and experience, John is a frequent speaker on technology, intellectual property, and commercial law topics.
Adobe in IP aspects of its US$1.68bn acquisition of Magento Commerce.
eBay in IP aspects of its acquisition of Giosis Pte Ltd's Japan Retailer, including Qoo10.
Intel Corporation in IP aspects of the sale of its interests in its IMS Nanofabricaion GmbH business for $4.3 billion.
Marvell Technology Group in IP aspects of its US$10bn acquisition of Inphi.
Applied Materials in IP and commercial aspects of its formation of its Elevated Materials joint venture with TPG Global, LLC.
Salesforce in IP aspects of its acquisition, of Datorama, Own Company, and Zoomin Software Ltd.
Recordati in IP and commercial aspects of its acquisition of Enjaymo® from Sanofi